Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
THRB antisense RNA 2 (THRB-AS2)
- Target
- THRB-AS2
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA
01
Overview
THRB antisense RNA 2 (THRB-AS2) is a long non-coding RNA that originates from the antisense strand of the thyroid hormone receptor beta (THRB) gene. It does not encode a protein and functions primarily at the RNA level, serving as a transcriptional activator for multiple promoter regions, independent of thyroid hormone signaling. THRB-AS2 acts broadly on gene expression, and its function does not require translation into protein. Its detailed physiological and pathological roles remain under study, and as of now, it is not directly linked to specific diseases or clinical therapeutic interventions.
- Other names
- THRB-AS2
02
Mechanism of action
Not applicable; no drugs act directly on THRB-AS2. Mechanistically, THRB-AS2 functions as an RNA molecule and not as a protein or receptor; it stimulates promoter activity and may act globally as a transcriptional activator, possibly interacting with chromatin or transcriptional machinery.
03
Biological functions
Regulation of gene expressionTranscriptional activation (stimulates activities of multiple promoters regardless of thyroid hormone response elements)RNA-dependent and transcription-dependent regulatory mechanisms (likely acts as a general transcriptional activator in trans)
04
Disease associations
The direct role of THRB-AS2 in disease is not established. Antisense lncRNAs in general are known to have implications in cancer, epigenetics, and gene regulatory disorders; however, as of current data, THRB-AS2’s disease association is undefined.
05
Safety considerations
None reported. THRB-AS2 is a regulatory RNA, not a pharmacological target, so there are no known therapeutic safety challenges associated directly with this molecule.
06
Interacting drugs
None reported. No approved or investigative drugs targeting THRB-AS2 have been documented in current sources.
07
Biomarkers
None specific. THRB-AS2 is not currently used as a biomarker for patient selection or efficacy monitoring.
Beyond the preview
Go deeper on THRB antisense RNA 2 (THRB-AS2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on THRB antisense RNA 2 (THRB-AS2).